Genetic modifiers of menopausal hormone replacement therapy and breast cancer risk: a genome-wide interaction study

Anja Rudolph, Rebecca Hein, Sara Lindström, Lars Beckmann, Sabine Behrens, Jianjun Liu, Hugues Aschard, Manjeet K Bolla, Jean Wang, Thérèse Truong, Emilie Cordina-Duverger, Florence Menegaux, Thomas Brüning, Volker Harth, Gianluca Severi, Laura Baglietto, Melissa Southey, Stephen J Chanock, Jolanta Lissowska, Jonine D FigueroaMikael Eriksson, Keith Humpreys, Hatef Darabi, Janet E Olson, Kristen N Stevens, Celine M Vachon, Julia A Knight, Gord Glendon, Anna Marie Mulligan, Alan Ashworth, Nicholas Orr, Minouk Schoemaker, Penny M Webb, Pascal Guénel, Hiltrud Brauch, Graham Giles, Montserrat García-Closas, Kamila Czene, Georgia Chenevix-Trench, Fergus J Couch, Irene L Andrulis, Anthony Swerdlow, David J Hunter, Dieter Flesch-Janys, Douglas F Easton, Per Hall, Heli Nevanlinna, Peter Kraft, Jenny Chang-Claude, GENICA Network

    23 Citationer (Scopus)

    Abstract

    Women using menopausal hormone therapy (MHT) are at increased risk of developing breast cancer (BC). To detect genetic modifiers of the association between current use of MHT and BC risk, we conducted a meta-analysis of four genome-wide case-only studies followed by replication in 11 case-control studies. We used a case-only design to assess interactions between single-nucleotide polymorphisms (SNPs) and current MHT use on risk of overall and lobular BC. The discovery stage included 2920 cases (541 lobular) from four genome-wide association studies. The top 1391 SNPs showing P values for interaction (Pint)
    OriginalsprogEngelsk
    TidsskriftEndocrine - Related Cancer
    Vol/bind20
    Udgave nummer6
    Sider (fra-til)875-87
    Antal sider13
    ISSN1351-0088
    DOI
    StatusUdgivet - dec. 2013

    Fingeraftryk

    Dyk ned i forskningsemnerne om 'Genetic modifiers of menopausal hormone replacement therapy and breast cancer risk: a genome-wide interaction study'. Sammen danner de et unikt fingeraftryk.

    Citationsformater